Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.36 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9944945 | 0.90 | POLB (0.41) | POLBALDH1A1GPR174MAPTMAPK1 | |
| SCHEMBL9944836 | 0.90 | POLB (0.41) | POLBALDH1A1GPR174MAPTMAPK1 | |
| SCHEMBL9944884 | 0.85 | NPC1 (0.38) | NPC1RAB9A | |
| SCHEMBL9944881 | 0.85 | ALDH1A1 (0.42) | POLBALDH1A1GPR174MAPTMAPK1 | |
| SCHEMBL9944825 | 0.84 | POLB (0.44) | POLBALDH1A1GPR174MAPTMAPK1 | |
| SCHEMBL9944914 | 0.84 | ALDH1A1 (0.42) | POLBALDH1A1GPR174MAPTMAPK1 | |
| SCHEMBL9944743 | 0.82 | MAPT (0.42) | POLBALDH1A1GPR174MAPTMAPK1 | |
| SCHEMBL9945015 | 0.81 | MAPT (0.42) | POLBALDH1A1GPR174MAPTMAPK1 | |
| SCHEMBL9944774 | 0.81 | L3MBTL1 (0.48) | POLBALDH1A1MAPTMAPK1L3MBTL1 | |
| SCHEMBL9945026 | 0.81 | CTPS1 (0.45) | POLBALDH1A1GPR174MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | POLB 2315/4885ALDH1A1 126/4885GPR174 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.